[ad_1]
The European Medicines Agency (EMA) has assessed the risk of nitrosamine formation or presence during the manufacture of human medicines. EMA has also provided guidance to marketing authorisation holders to avoid the presence of nitrosamine impurities.
[ad_2]
Source link